BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer

Published:2007-11-07 Issue:11 Volume:2 Page:e1129
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Rosell Rafael,Skrzypski Marcin,Jassem Ewa,Taron Miquel,Bartolucci Roberta,Sanchez Jose Javier,Mendez Pedro,Chaib Imane,Perez-Roca Laia,Szymanowska Amelia,Rzyman Witold,Puma Francesco,Kobierska-Gulida Grazyna,Farabi Raffaele,Jassem Jacek

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference47 articles.

1. Estimates of the cancer incidence and mortality in Europe in 2006.;J Ferlay;Ann Oncol,2007

2. Adjuvant chemotherapy of lung cancer: methodologic issues and therapeutic advances.;GM Strauss;Hematol Oncol Clin North Am,2005

3. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial.;JY Douillard;Lancet Oncol,2006

4. A cross-study comparison of gene expression studies for the molecular classification of lung cancer.;G Parmigiani;Clin Cancer Res,2004

5. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.;A Potti;N Engl J Med,2006

Cited by 185 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Establishing the role of BRCA1 in the diagnosis, prognosis and immune infiltrates of breast invasive cancer by bioinformatics analysis and experimental validation;Aging;2024-01-13

2. Prognostic Value of Chromatin Structure Typing in Early-Stage Non-Small Cell Lung Cancer;Cancers;2023-06-13

3. Epigenetics of cisplatin resistance;Epigenetic Cancer Therapy;2023

4. Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer;Frontiers in Oncology;2022-12-14

5. International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer;Annals of Oncology;2022-01